



'A War Brewing' Over GLP-1 Agonist Production
NOVEMBER 21, 2024



Benefits of Shingles Vaccine Outweigh Risks for the Immunocompromised
NOVEMBER 21, 2024



Health-System SPs Champion Holistic Oncology Care
NOVEMBER 21, 2024



NOVEMBER 19, 2024

Ibuprofen Injection Shows Better Real-World Outcomes in Comparative Study

Originally published by our sister publication [Pain Medicine News](#)

New real-world outcomes research demonstrated the safety and healthcare resource advantages of ibuprofen injection (Caldolor, Cumberland Pharmaceuticals) over ketorolac in both adult and pediatric populations.



The study, published in *Frontiers of Pain Research* ([Front Pain Res](#) 24;5: doi:10.3389/fpain.2024.1484948), “provides compelling evidence,” according to the company in a statement, that ibuprofen injection is associated with a significantly reduced incidence of adverse drug reactions and improved healthcare utilizations when compared to ketorolac.

The retrospective, payer database analysis evaluated the records of over 17 million patients who had received either ketorolac or ibuprofen. Ultimately, 31,046 ibuprofen injection and 124,184 ketorolac adult patients were selected and compared for adverse drug reactions and subsequent healthcare resource utilization. This includes inpatient, outpatient and emergency department visits as well as all procedures and prescriptions during the follow up time of 29 days. An additional 5,579 pediatric patients were identified in each arm and compared in a separate claims analysis.

Ibuprofen injection treatment in adults was associated with a 45% reduction in renal dysfunction (P<0.001) and a 78% decrease in hematuria rates (P<0.001) when compared to ketorolac. Notably, patients also experienced fewer gastrointestinal complications and headaches, and less nausea and abdominal pain. Among pediatric patients, ibuprofen injection was associated with a 51% to 65% lower rate of adverse drug events, including headache and nausea, with 95% confidence intervals supporting clinical significance.

Ibuprofen injection also demonstrated a positive effect on healthcare resource utilization when compared to ketorolac, with decreased emergency room and outpatient visits, as well as a shortened hospital length of stay for both adults and children.

Ibuprofen injection indicated in adults and pediatric patients for the management of mild-to-moderate pain and management of moderate-to-severe pain as an adjunct to opioid analgesics, as well as the reduction of fever. It is contraindicated in patients with known hypersensitivity to ibuprofen or other non-steroidal inflammatory drugs (NSAIDs), as well as patients with a history of asthma or other allergic type reactions after taking aspirin or other NSAIDs. Ibuprofen injection is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft surgery.

Based on a press release from Cumberland Pharmaceuticals Inc.

Related Content

[In Patients With Chronic, Noncancer Pain ...](#)

[Questionnaire Helps Screen Patients at Risk for Opioid Abuse](#)

[Drug Theft in Pharmacy: No Idle Diversion](#)

Related Keywords

[pain](#)

[ibuprofen](#)

[ketorolac](#)

[ibuprofen injection](#)

More in Clinical

CNS Involvement in Immunocompromised Shingles Patients: Don't Miss the Subtle Signs

A retrospective case series study of immunocompromised patients with active herpes zoster infections who presented for care with skin lesions and subtle neurologic manifestations found that 100% had a positive test for the virus in their CSF.

NOVEMBER 21, 2024

Drug-Resistant *Candida auris* Has a Health Equity Component

With *Candida auris* cases surging by more than 200% between 2019 and 2021 in the United States, this emerging multidrug-resistant fungal pathogen has become a significant public health concern, according to the CDC.

NOVEMBER 21, 2024

Rapid Pneumonia Panel Guides ABx Discontinuation

A rapid multiplexed molecular panel led to a significant reduction in the number of total days on antibiotics with no increases in in-hospital mortality, length of stay or readmission, according to study results presented at IDWeek 2024, in Los Angeles.

NOVEMBER 20, 2024



FDA News



FDA Approves Revuforj for Relapsed or Refractory Acute Leukemia With a KMT2A Translocation

The FDA approved Revuforj, a menin inhibitor, for relapsed or refractory acute leukemia with a lysine ...



FDA Approves Aucatzyl for Adults With Relapsed or Refractory B-Cell Precursor ALL

The FDA approved Aucatzyl, a CD19-directed genetically modified autologous T-cell immunotherapy, for adults with ...

Most Popular

7 Tips for Meeting The Joint Commission's Sterile Compounding Requirements in 2024

OPERATIONS & MANAGEMENT SEPTEMBER 25, 2024

New Guideline for *H. pylori* Changes Primary Treatment Recommendation

CLINICAL SEPTEMBER 24, 2024

FDA Grants Reprieve on Enhanced DSCSA Requirements With New Phased-In Deadlines

ONLINE FIRST OCTOBER 11, 2024

FDA and State Boards Eye GLP-1s Amid Larger Compounding Scrutiny

POLICY OCTOBER 4, 2024

FDA News



FDA Approves Revuforj for Relapsed or Refractory Acute Leukemia With a KMT2A Translocation

The FDA approved Revuforj, a menin inhibitor, for relapsed or refractory acute leukemia with a lysine ...



FDA Approves Aucatzyl for Adults With Relapsed or Refractory B-Cell Precursor ALL

The FDA approved Aucatzyl, a CD19-directed genetically modified autologous T-cell immunotherapy, for adults with ...

Archives

November 2024	October 2024
September 2024	August 2024

[MORE](#)



Pharmacy Practice News provides health-system pharmacists with accurate, relevant and up-to-date information that improves clinical practice. PPN offers news as well as regular features focusing on medication safety, technology, compounding, accreditation, reimbursement, innovative practice models, pipeline drugs and new FDA drug approvals, as well as our renowned clinical reviews of top therapeutic categories. PPN is perennially ranked No. 1 in key readership categories among decision makers.


eNewsletter

[Click here](#) to sign up to receive our eNewsletter.

My Account

[LOGIN](#)
[REGISTER](#)

Social Media



McMahon Websites

- Anesthesiology News
- Clinical Oncology News
- Gastroenterology & Endoscopy News
- General Surgery News
- Infectious Disease Special Edition
- Pain Medicine News
- Pharmacy Practice News
- Specialty Pharmacy Continuum
- CMEZone.com
- McMahon Custom Media
- McMahon Group
- Pharmacy Technology Report
- OR Management News

- [HOME](#)
- [ABOUT](#)
- [SUBSCRIPTION](#)
- [ADVERTISE](#)
- [CONTACT](#)
- [ARCHIVES](#)
- [PRIVACY POLICY](#)